Remarks

The Office Action acknowledged Applicant's election of compound 1.B.68 filed October 25, 2004, modified the scope of the genus and withdrew claims 17 and 18 from consideration as being "not so linked to form a single inventive concept".

Applicants have amended claims 15 and 16 to be consistent with the modified genus. Applicants have also amended claim 17 to be of the same scope and request reconsideration of its withdrawal on the grounds that they have the same inventive concept since they both have the structural element G-L which is the gist of the present invention. Elements G and L are mainly responsible for the spatial structure of the compounds of claim 15 and are of substantial importance in the specific PARP inhibiting effect of these compounds.

The Office Action rejected claims 15, 16 and 19-22 under 35 U.S.C. §112, second paragraph, as being indefinite. Claims 20 and 21 have been cancelled and independent claims 15 and 16 have been amended to specify the optional substituents on the various R groups and G. Support for this Amendment may be found at page 11, line 20-page 12-line 2, page 14, lines 28-32, page 15, lines 15-17, page 22, line 5-9, page 22, lines 16-18, page 23, lines 4-7, page 24, lines 4-22, page 25, lines 4-36 and page 25, line 45 to page 26, line 8.

Claims 20 and 21 have also been rejected under 35 U.S.C. §112, first paragraph. Since these claims have been cancelled, this rejection is now moot.

Applicants have amended claim 22 as a method of treatment claim to enumerated diseases using the compounds of claim 15.

Favorable consideration and allowance of claims 15-17, 19-22 as presented amended is respectfully requested.

If any fees are incurred as a result of the filing of this paper, authorization is given to charge Deposit Account No. 23-0785.

Respectfully submitted,

WOOD, PHILLIPS, KATZ, CLARK & MORTIMER

Martin L. Katz, Reg. No. 25,011

Date: March 21, 2005

Citicorp Center, Suite 3800 500 W. Madison Street Chicago, IL 60661-2511 (312) 876-1800